Search

Search Constraints

You searched for: Author/Creator LoRusso, Patricia

Search Results

1. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors. Issue 1 (December 2016)

2. Improving attribution of adverse events in oncology clinical trials. (June 2019)

3. Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. Issue 9 (30th October 2018)

4. Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors. Issue 1 (25th May 2018)

5. 404 ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC). (10th December 2020)

6. 807 A multicenter open-label phase I/lb study of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors. (9th November 2020)

7. 412 First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors. (10th December 2020)

8. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Issue 10241 (20th June 2020)

9. Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3‐Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations. (8th August 2019)

10. Incidence of Mucositis in Patients Treated With Temsirolimus-Based Regimens and Correlation to Treatment Response. (25th March 2014)